Evidence map›Paper›PMID 37218017›Full record

ArticleTrials2023

Correction: Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE).

Tania A Smith, Carlos Hoyo-Vadillo, Akosua Agyeman Adom, Liliana Favari-Perozzi, Silke Gastine, Hakim-Moulay Dehbi, Beatriz Villegas-Lara, Eduardo Mateos, Yessica Sara Pérez González, Maria D Navarro-Gualito and 10 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Tania A SmithCINVESTAV-IPN, Mexico, Mexico. tania.smith@cinvestav.mx.ORCID http://orcid.org/0000-0003-4486-3839
Carlos Hoyo-VadilloCINVESTAV-IPN, Mexico, Mexico.
Akosua Agyeman AdomICH-UCL, London, UK.
Liliana Favari-PerozziCINVESTAV-IPN, Mexico, Mexico.
Silke GastineICH-UCL, London, UK.
Hakim-Moulay DehbiClinical Trials Unit, UCL, London, UK.
Beatriz Villegas-LaraIMSS, Mexico, Mexico.
Eduardo MateosIMSS, Mexico, Mexico.
Yessica Sara Pérez GonzálezIMSS, Mexico, Mexico.
Maria D Navarro-GualitoIMSS, Mexico, Mexico.
Alejandra S Cruz-CarbajalIMSS, Mexico, Mexico.
Miguel A Cortes-VazquezIMSS, Mexico, Mexico.
Carolina Bekker-MéndezIMSS, Mexico, Mexico.
Charmina Aguirre-AlvaradoIMSS, Mexico, Mexico.
Gisela Aguirre-GilHakken Enterprise, Cuernavaca, Mexico.
Lucero Delgado-PastelinHakken Enterprise, Cuernavaca, Mexico.
Andrew OwenUniversity of Liverpool, Liverpool, UK.
David LoweDivision of Infection and Immunity, UCL, London, UK.
Joseph StandingICH-UCL, London, UK.
Jorge EscobedoIMSS, Mexico, Mexico.
Mexican Social Security Institute · MXUniversity College London · GBCentro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MXMRC Clinical Trials Unit at UCL · GBUniversity of Liverpool · GB

Funding

Medical Research Council MR/M008665/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37218017
PMCPMC10201498
OpenAlexW4377292121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.